The use of SGLT2 inhibitors, especially dapagliflozin, can lower adiposopathy parameters in patients with CKD, regardless of diabetes status, a cohort study finds.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/sglt2-inhibitors-can-modulate-adiposopathy-ckd-2025a100104n?src=rss
Author :
Publish date : 2025-12-25 12:00:00
Copyright for syndicated content belongs to the linked Source.